CLINICAL EFFECTIVENESS OF BUDESONIDE AND FORMOTEROL IN A SINGLE INHALER IN PATIENTS WITH ASTHMA - AN AUDIT IN UK GENERAL PRACTICE
Author(s)
Emmas CE1, Beaumont SD2, 1AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom; 2AstraZeneca UK, Luton, Bedfordshire, United Kingdom
OBJECTIVES: Randomised controlled clinical trials demonstrate how well treatments work under ideal conditions (clinical efficacy). However, once efficacy has been established there is a need to show how well treatment work in the less ideal conditions of normal clinical practice (clinical effectiveness). This study is the first to demonstrate the clinical effectiveness of budesonide/formoterol in a single inhaler in the treatment of asthma in UK general practice. METHODS: Patients with inadequately controlled asthma were identified following a review of their patient notes and a consultation with a clinical nurse specialist using criteria agreed with the general practitioner. These patients were referred to the doctor for a treatment review and a subsequent assessment at six months. RESULTS: As a result of the review 119 patients, previously treated with =200mcg inhaled corticosteroid daily, received budesonide/formoterol (80/4.5mcg or 160/4.5mcg 1-2 puffs twice daily) in a single inhaler for the first time. Improvements were observed in all measures of health outcomes. There was a significant increase in the mean peak expiratory flow between initial (415L/min) and 6 month (447L/min) assessments (p<0.0001). Patients reported a greater proportion of symptom-free days (p<0.0001) fewer episodes of symptoms in the day (p<0.0001) and at night (p<0.0001). They reported a reduced use of reliever medication (p<0.0001) and a reduction of exercise induced asthma (p<0.0001). There was a significant decrease in routine asthma-related primary care consultations (p<0.0005) and fewer emergency GP visits (p<0.001). Patients understood their treatment better (p<0.0001), were concerned about their asthma for less of the time (p<0.0001), and 98% of patients felt they had benefited from taking part in the programme of which this change in therapy was a part. CONCLUSIONS: In this group of asthmatic patients, inadequately controlled on =200mcg inhaled corticosteroid daily, budesonide/formoterol in a single inhaler provided significant improvements, which demonstrate superior clinical effectiveness.
Conference/Value in Health Info
2003-05, ISPOR 2003, Arlington, VA, USA
Value in Health, Vol. 6, No. 3 (May/June 2003)
Code
PRP3
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Respiratory-Related Disorders